Needle exchange is not enough: lessons from the Vancouver injecting drug use study
SA Strathdee, DM Patrick, SL Currie, PGA Cornelisse… - Aids, 1997 - journals.lww.com
Objective: To describe prevalence and incidence of HIV-1, hepatitis C virus (HCV) and risk
behaviours in a prospective cohort of injecting drug users (IDU). Setting: Vancouver, which …
behaviours in a prospective cohort of injecting drug users (IDU). Setting: Vancouver, which …
Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection
…, K Li, CH Sherlock, ML Rekart, SA Strathdee, SL Currie… - Cmaj, 2001 - Can Med Assoc
Background: Beginning in 1994, Vancouver experienced an explosive outbreak of HIV
infection among injection drug users (IDUs). The objectives of this study were to measure the …
infection among injection drug users (IDUs). The objectives of this study were to measure the …
Hepatitis C virus infection among prisoners in the California state correctional system
…, SL Currie, J Evans, TL Wright, L Tobler… - Clinical Infectious …, 2005 - academic.oup.com
Background .Incarcerated populations are at high risk for hepatitis C virus (HCV) infection,
yet prisoners are not routinely screened or treated for HCV infection. Understanding the risk …
yet prisoners are not routinely screened or treated for HCV infection. Understanding the risk …
Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the …
HS Yee, SL Currie, JM Darling… - Official journal of the …, 2006 - journals.lww.com
Chronic hepatitis C virus (HCV) infection affects approximately 1.3% of the general US
population and 5–10% of veterans who use Department of Veterans Affairs medical services. …
population and 5–10% of veterans who use Department of Veterans Affairs medical services. …
[HTML][HTML] Bempegaldesleukin plus nivolumab in first-line metastatic melanoma
…, E Puente, T Nguyen, U Hoch, SL Currie… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Therapies that produce deep and durable responses in patients with metastatic
melanoma are needed. This phase II cohort from the international, single-arm PIVOT-02 …
melanoma are needed. This phase II cohort from the international, single-arm PIVOT-02 …
A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus
SL Currie, JC Ryan, D Tracy, TL Wright… - Drug and alcohol …, 2008 - Elsevier
BACKGROUND: Many HCV-infected persons with recent or ongoing injection drug use (IDU)
do not receive HCV treatment due to the perceived risk of HCV reinfection. There are few …
do not receive HCV treatment due to the perceived risk of HCV reinfection. There are few …
Treatment with etirinotecan pegol for patients with metastatic breast cancer and brain metastases: final results from the phase 3 ATTAIN randomized clinical trial
Importance Patients with breast cancer and brain metastases (BM) have a poor prognosis
and high clinical need for novel treatments; however, historically, studies have often excluded …
and high clinical need for novel treatments; however, historically, studies have often excluded …
[HTML][HTML] Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
…, U Hoch, A Choudhury, D Yu, SL Currie… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Immune checkpoint inhibitor-based combinations have expanded the
treatment options for patients with renal cell carcinoma (RCC); however, tolerability remains …
treatment options for patients with renal cell carcinoma (RCC); however, tolerability remains …
Bempegaldesleukin plus nivolumab in first-line metastatic urothelial carcinoma: results from PIVOT-02
… Sue L. Currie is a former employee of and holds stock and other ownership interests in
Nektar Therapeutics. Lily Tang, Ute Hoch, Arkopal Choudhury, and Danni Yu are employees of …
Nektar Therapeutics. Lily Tang, Ute Hoch, Arkopal Choudhury, and Danni Yu are employees of …
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence
Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug
engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab …
engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab …
